[A case of fatal clinical course with reversible acute cardiac failure and glucose intolerance during sorafenib therapy for metastatic renal cell carcinoma].

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Hinyokika kiyo. Acta urologica Japonica

• Publication date

  2012-08-01

• Fields of study

  Medicine

• Identifiers
  PMID 23052271
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Overall survival and good tolerability of long‐term use of sorafenib after cytokine treatment: final results of a phase II trial of sorafenib in Japanese patients with metastatic renal cell carcinoma

  2011cited by this paper
• Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice

  2011cited by this paper
• Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma

  2009cited by this paper
• [Two cases of renal cell carcinoma with diabetes mellitus that was healed after nephrectomy].

  2007cited by this paper
• Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma.

  2007cited by this paper
• Sorafenib in advanced clear-cell renal-cell carcinoma.

  2007cited by this paper
• Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.

  2006cited by this paper
• BAY 43-9006: preclinical data.

  2002cited by this paper
• Hypoglycaemia caused by secretion of insulin-like growth factor 2 in a primary renal cell carcinoma.

  2001cited by this paper
• Circulating interleukin 6 concentrations and insulin resistance in patients with cancer

  1998cited by this paper
• Role of interleukin‐6 in the paraneoplastic inflammatory syndrome associated with renal‐cell carcinoma

  1997cited by this paper
• INAPPROPRIATELY ELEVATED PLASMA INSULIN‐LIKE GROWTH FACTOR II IN RELATION TO SUPPRESSED INSULIN‐LIKE GROWTH FACTOR I IN THE DIAGNOSIS OF NON‐ISLET CELL TUMOUR HYPOGLYCAEMIA

  1990cited by this paper
• Inhibition of insulin secretion from rat islets of Langerhans by interleukin-6. An effect distinct from that of interleukin-1.

  1990cited by this paper

• Risk of treatment-related mortality with sorafenib in cancer patients: a meta-analysis of 20 randomly controlled trials

  2015cites this paper